Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Dynamics of cytotoxic T c… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia

Artikel i vetenskaplig tidskrift
Författare Frida Ewald Sander
Anna Rydström
Elin Bernson
Roberta Kiffin
Rebecca E Riise
Johan Aurelius
H. Anderson
Mats Brune
R. Foa
Kristoffer Hellstrand
Fredrik Bergh Thorén
Anna Martner
Publicerad i Oncotarget
Volym 7
Nummer/häfte 7
Sidor 7586-7596
ISSN 1949-2553
Publiceringsår 2016
Publicerad vid Sahlgrenska Cancer Center
Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Sidor 7586-7596
Språk en
Länkar dx.doi.org/10.18632/oncotarget.7210
Ämnesord acute myeloid leukemia, immunotherapy, cytotoxic T cells, antigen-specific T cells, Immunology and, histamine dihydrochloride, transplantation, memory, differentiation, interleukin-2, lymphocytes, maintenance, remission, responses, effector, Oncology, Cell Biology
Ämneskategorier Klinisk medicin

Sammanfattning

Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (ClinicalTrials.gov; NCT01347996). Blood samples were drawn during cycles of immunotherapy and analyzed for CD8(+) (cytotoxic) T cell phenotypes in blood. During the first cycle of therapy, a re-distribution of cytotoxic T cells was observed comprising a reduction of T effector memory cells and a concomitant increase of T effector cells. The dynamics of T cell subtypes during immunotherapy prognosticated relapse and survival, in particular among older patients and remained significantly predictive of clinical outcome after correction for potential confounders. Presence of CD8(+) T cells with specificity for leukemia-associated antigens identified patients with low relapse risk. Our results point to novel aspects of T cell-mediated immunosurveillance in AML and provide conceivable biomarkers in relapse-preventive immunotherapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?